TW200640466A - Method of treatment - Google Patents

Method of treatment

Info

Publication number
TW200640466A
TW200640466A TW095100687A TW95100687A TW200640466A TW 200640466 A TW200640466 A TW 200640466A TW 095100687 A TW095100687 A TW 095100687A TW 95100687 A TW95100687 A TW 95100687A TW 200640466 A TW200640466 A TW 200640466A
Authority
TW
Taiwan
Prior art keywords
related disorders
disorders
substance
pharmaceutically acceptable
limited
Prior art date
Application number
TW095100687A
Other languages
Chinese (zh)
Inventor
Patricia C Davis
Jeffrey M Goldstein
Scott W Grimm
Helen R Winter
Raymond F Suckow
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TW200640466A publication Critical patent/TW200640466A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method of treating at least one symptom or condition associated with but not limited to: (1) Substance-Related Disorders including but not limited to Substance Dependence, Substance Abuse, Substance Intoxication, Substance Withdrawal, Alcohol-Related Disorders, Amphetamine (or Amphetamine-Like)-Related Disorders, Caffeine-Related Disorders, Cannabis-Related Disorders, Cocaine-Related Disorders, Hallucinogen-Related Disorders, Inhalant-Related Disorders, Nicotine-Related Disorders, Opioid-Related Disorders, Phencyclidine (or Phencyclidine-Like)-Related Disorders, and Sedative, Hypnotic- or Anxiolytic-Related Disorders. (2) Attention-Deficit and Disruptive Behavior Disorders. (3) Eating Disorders. (4) Personality Disorders including but not limited to Obsessive-Compulsive Personality Disorder. (5) Impulse-Control Disorders, comprising administering an effective amount of formula I, or its pharmaceutically acceptable salt. In another aspect of the invention a pharmaceutical composition is provided comprising an effective amount of Formula I or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier or diluent.
TW095100687A 2005-01-07 2006-01-06 Method of treatment TW200640466A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US64226205P 2005-01-07 2005-01-07
US73786405P 2005-11-18 2005-11-18
US73786505P 2005-11-18 2005-11-18
US73788705P 2005-11-18 2005-11-18

Publications (1)

Publication Number Publication Date
TW200640466A true TW200640466A (en) 2006-12-01

Family

ID=36647771

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095100687A TW200640466A (en) 2005-01-07 2006-01-06 Method of treatment

Country Status (6)

Country Link
EP (1) EP1838325A1 (en)
JP (1) JP2008526839A (en)
AR (1) AR052191A1 (en)
TW (1) TW200640466A (en)
UY (1) UY29326A1 (en)
WO (1) WO2006073360A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101360503A (en) * 2005-11-18 2009-02-04 阿斯利康公司 Liquid formulations
DK2307389T3 (en) 2008-06-20 2013-04-02 Astrazeneca Ab Dibenzothiazepine derivative and uses thereof
US8389716B2 (en) 2009-01-30 2013-03-05 F.I.S. Fabbrica Italiana Sintetici S.P.A. Process for the synthesis of quetiapine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US7071133B2 (en) * 1993-11-16 2006-07-04 Ppg Industries Ohio, Inc. Colored glass compositions and-automotive vision panels with-reduced transmitted-color shift
US5602124A (en) * 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. 5-HT2 receptor ligands
SE0003126D0 (en) * 2000-09-05 2000-09-05 Astrazeneca Ab Method of treatment
US7304047B2 (en) * 2001-02-06 2007-12-04 Astrazeneca Ab Method of treating substance abuse with quetiapine
US20060189599A1 (en) * 2002-10-18 2006-08-24 Green Alan I Treating alcohol and or substance abuse by antagonizing alpha 2 adrenergic receptors with weak dopamine blocking
AU2004253334A1 (en) * 2003-07-02 2005-01-13 Astrazeneca Ab Metabolite of quetiapine
US20070270403A1 (en) * 2003-12-04 2007-11-22 Broderick Patricia A Clozapine and Cocaine Effects on Dopamine and Serotonin Release in Nucleus Accumbens During Psychostimulant Behavior and Withdrawal
US7550454B2 (en) * 2003-12-22 2009-06-23 Acadia Pharmaceuticals, Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic

Also Published As

Publication number Publication date
AR052191A1 (en) 2007-03-07
WO2006073360A1 (en) 2006-07-13
EP1838325A1 (en) 2007-10-03
UY29326A1 (en) 2006-08-31
JP2008526839A (en) 2008-07-24

Similar Documents

Publication Publication Date Title
WO2006060507A3 (en) Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
MX2008001549A (en) 3, hb cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses.
MA28469B1 (en) INHIBITORS OF DIPEPTIDYL PEPTIDASE
ATE548354T1 (en) UREIDO-SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND TREATMENT OF DISEASES
HK1117083A1 (en) Compositions and methods for treatment of eye disorders
WO2004037169A3 (en) Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2003082817A3 (en) Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2007006003A3 (en) Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
WO2006017673A3 (en) Taj in neuronal function
ATE397930T1 (en) USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS TO TREAT ANTHRAX AND OTHER INFECTIONS
WO2007005896A3 (en) Anti-tubercular drugs: compositions and methods
GB0510143D0 (en) Novel compounds A1
NZ593061A (en) Hemifumarate salt of 1- [4- [1- ( 4 -cyclohexyl-3 -trifluoromethyl-benzyloxyimino ) -ethyl] -2 -ethyl-benzyl] -azetidine-3-carboxylic acid
MY142252A (en) Pyrrolopyridine-based inhibitors of dipeptidyl peptidase iv and methods
TW200640466A (en) Method of treatment
TW200616644A (en) Medicine for prevention or treatment of diabetes
MXPA05009014A (en) Ccr-3 receptor antagonists.
DE602004015089D1 (en) PYRROLOIMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, THESE INGREDIENT COMPOSITIONS, AND THEIR USE AS NOOTROPIKA
TW200503726A (en) Use of dihydroimidazolones for the treatment of dogs
Bowen et al. Lithium and marijuana withdrawal
ATE326223T1 (en) METHOD OF TREATING HYPERACTIVE BLADDER
WO2005007239B1 (en) Use of dapsone as a neuroprotector in cerebral infarction
TW200630097A (en) Methods of using PDE V inhibitors for the treatment of congestive heart failure
ATE411810T1 (en) LAMINARINE OR OLIGOLAMINARIN MEDICINE FOR THE TREATMENT OF SEPTICAEMIA AND SHOCK
MX2009009409A (en) Compounds having aryl-sulphonamidic structure useful as metalloproteases inhibitors.